Tofersen was approved under the FDA’s accelerated approval process on 25th Apr, 2023, because it treats a life-threatening condition—ALS caused by a mutation in the SOD1 gene for which there are yet no therapies [144]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.